Psyence Biomedical Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Selling, General & Admin	4.77	3.32	1.8	1.63
Depreciation & Amortization Expenses	0.01	0	0	-
Research & Development	1.47	0.34	0.95	1.61
Total Operating Expenses	6.24	3.66	2.75	3.23
Operating Income	-6.24	-3.66	-2.75	-3.23
Interest Income	0.26	0.1	0	0
Interest Expense	-0.01	-0.01	-0.05	-
Other Non-Operating Income (Expense)	-0.95	4.59	-48.36	0.03
Total Non-Operating Income (Expense)	-0.7	4.67	-48.41	0.03
Pretax Income	-6.94	1.01	-51.16	-3.21
Net Income	-6.94	1.01	-51.16	-3.21
Net Income to Common	-6.94	1.01	-51.16	-3.21
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	1	0	-	-
Shares Outstanding (Diluted)	1	0	-	-
Shares Change	1688.07%	-	-	-
EPS (Basic)	-12.56	32.76	-	-
EPS (Diluted)	-12.56	32.76	-	-
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Free Cash Flow	-8.14	-3.74	-2.95	-1.59
Free Cash Flow Growth	-	-	-	-
Free Cash Flow Per Share	-14.74	-121.22	-	-
EBITDA	-6.23	-3.66	-2.75	-3.23
EBIT	-6.24	-3.66	-2.75	-3.23

SEC Filings: 10-K · 10-Q